SLU-PP-332 Tablets

Description

SLU-PP-332 (ERRα/β/γ Pan-Agonist / Exercise-Mimetic Small-Molecule Analog)

Available Forms & Strengths:

• 250 mcg per tablet — 60 tablets per bottle

• 500 mcg per tablet — 60 tablets per bottle

• 1 mg per tablet — 60 tablets per bottle

• 20 mg per tablet — 30 tablets per bottle

Molecular Formula: C₁₈H₁₄N₂O₂
Molecular Weight: 290.32 g/mol
CAS Number: 303760-60-3
Purity: ≥98 % (HPLC)
Storage: Store in a cool, dry place away from light and moisture.

Description

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ), a family of nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, and energy expenditure.
It is frequently described as an exercise-mimetic compound, capable of activating metabolic gene programs similar to those induced by aerobic training.

Preclinical studies show that SLU-PP-332 enhances fatty-acid oxidation, increases mitochondrial number and function, and elevates basal metabolic rate without increasing physical activity.
By binding directly to ERR receptors, it promotes expression of genes involved in oxidative phosphorylation (OXPHOS), fat metabolism, and mitochondrial respiration, providing a valuable model for studying metabolic adaptation and endurance physiology.

Its receptor activation profile also makes it suitable for research on mitochondrial dysfunction, metabolic syndrome, and exercise-mimetic therapeutics, helping to elucidate how transcriptional control of energy metabolism can be pharmacologically regulated.

Intended Use

This product is intended for laboratory research use only.
It is not for human consumption, diagnostic, or therapeutic applications.
All handling should be performed by qualified professionals in a controlled research environment.

Key Research Applications

• Investigation of ERRα/β/γ receptor activation and transcriptional regulation

• Studies on mitochondrial biogenesis, oxidative phosphorylation, and fat oxidation

• Research on metabolic adaptation and endurance-mimetic pathways

• Analysis of ERR signaling as a therapeutic target for obesity and metabolic disorders